Insulet Corporation $PODD Stock: Russell Investments Group Ltd. Lowers Stake

Russell Investments Group Ltd. reduced its stake in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 11.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 144,742 shares of the medical instruments supplier’s stock after selling 19,100 shares during the period. Russell Investments Group Ltd.’s holdings in Insulet were worth $18,899,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Insulet during the second quarter worth $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its stake in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the period. Man Group plc acquired a new position in Insulet in the 2nd quarter worth $78,746,000. Amundi boosted its stake in Insulet by 13.6% in the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after purchasing an additional 60,929 shares during the period. Finally, Bank of America Corp DE acquired a new position in Insulet in the 2nd quarter worth $64,921,000.

Insulet Trading Down 3.7%

Shares of NASDAQ:PODD opened at $139.98 on Thursday. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a market capitalization of $9.71 billion, a P/E ratio of 22.80, a price-to-earnings-growth ratio of 1.11 and a beta of 1.06. The company has a 50-day simple moving average of $142.20 and a 200 day simple moving average of $171.85. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51.

Insulet (NASDAQ:PODD – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. During the same period in the previous year, the firm earned $1.24 EPS. The firm’s revenue was up 19.2% compared to the same quarter last year. Sell-side analysts forecast that Insulet Corporation will post 6.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PODD shares. Jefferies Financial Group restated a “buy” rating and issued a $200.00 price target on shares of Insulet in a report on Wednesday, November 4th. UBS Group upped their price objective on Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a report on Monday, September 21st. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Finally, Sanford C. Bernstein lifted their target price on Insulet from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Eleven equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $185.04.

View Our Latest Stock Analysis on Insulet

Insulet Profile

(Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Read More

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.